AI assistant
Vaxcyte, Inc. — Director's Dealing 2020
Jun 12, 2020
31100_dirs_2020-06-11_69786009-9295-4e4b-b1d7-5c6283fa0f7b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2020-06-11
Reporting Person: Sauer Paul (SVP Process Dev, Manufacturing)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 76615 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $0.80 | 2026-04-19 | Common Stock (8336) | Direct | |
| Stock Option (right to buy) | $1.79 | 2027-05-17 | Common Stock (28925) | Direct | |
| Stock Option (right to buy) | $2.03 | 2028-07-23 | Common Stock (70068) | Direct | |
| Stock Option (right to buy) | $2.03 | 2029-03-20 | Common Stock (29638) | Direct | |
| Stock Option (right to buy) | $5.35 | 2030-04-17 | Common Stock (65788) | Direct |
Footnotes
F1: The shares subject to the option are fully vested and exercisable.
F2: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. The original grant for 69,420 shares was exercised for 40,495 shares on July 29, 2019.
F3: 1/4 of the shares subject to the option vested on July 24, 2019, and 1/48 of the shares vest monthly thereafter.
F4: 1/4 of the shares subject to the option vested on January 1, 2020, and 1/48 of the shares vest monthly thereafter.
F5: 1/4 of the shares subject to the option vest on March 20, 2021, and 1/48 of the shares vest monthly thereafter.